Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
Shunichi Sugawara, Satoshi Oizumi, Koichi Minato et al. · Annals of Oncology · 2015
Cited by 110 works. doi:10.1093/annonc/mdv063
Authors
- Shunichi Sugawara
- Satoshi Oizumi
- Koichi Minato
- Toshiyuki Harada
- Akira Inoue
- Yasuko Fujita
- Makoto Maemondo
- Hirohisa Yoshizawa
- Ken‐ichi Ito
- Akihiko Gemma
- Masaru Nishitsuji
- M. Harada
- Hiroshi Isobe
- Ichiro Kinoshita
- Satoshi Morita
- Kunihiko Kobayashi
- Koichi Hagiwara
- M Kurihara
- T. Nukiwa
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)